On June 16th, 2020, ArisGlobal participated in the 2020 DIA Annual Meeting, where Sondra Pepe, Senior Director/Head of Clinical Product Management at ArisGlobal, presented “The Evolving Role of CTMS in Risk Management.”
During the event, Sondra highlighted some notably evolving areas in the clinical industry. These evolutions include rising development costs to run clinical trials, fewer drug approvals resulting from these trials and changes in ICH E6(R2), which have all had a critical impact on how clinical trials are run.
To properly respond to these challenges, best in class organizations are re-thinking their approach to risk assessment. Risk assessment not only helps ensure patient volunteers’ safety, but it also ensures regulatory compliance while identifying risks that could impact the safety, quality, or length of a trial. During the risk management process, it is integral to measure milestones, key risk indicators (KRIs), and key performance indicators (KPIs) to quickly assess data and then to determine conclusively if an action is necessary. Ideally, the risk management process needs to be taken out of a spreadsheet and processed via a clinical trial management system (CTMS), which can more easily facilitate these actions to achieve more accurate results.
ArisGlobal’s LifeSphere CTMS10 is an end-to-end solution that makes the entire clinical trial management process easier and more transparent for companies of all sizes. It enables simple, end-to-end clinical trial management in a single application, reducing complexity to empower organizations of all sizes while it automates key clinical trial activities to enhance productivity and deliver faster trials.
To learn more about how our clinical products can help your clinical trial endeavors through this evolving CTMS role in Risk Management, view our webinar here.
For more information on ArisGlobal’s LifeSphere Clinical Platform, view our factsheet here.
Download ArisGlobal’s 2024 Industry Report 
